692 AMV564, a clinically active T cell engager, induces a target-dependent adaptive immune response

by Victoria Smith, Patrick Chun, Curtis Ruegg, Sterling Eckard, Aurelien Sarde, Li Mei
Published 2020-11-01

372 Single-agent anti-tumor activity in relapsed/refractory solid tumors: interim data from the phase 1 solid tumor trial of AMV564, a novel T-cell engager

by Victoria Smith, Patrick Chun, Alexander Starodub, Sarina Piha-Paul, Raghad Karim, Michael Shafique, Gabriel Tinoco Suarez, Curtis Ruegg
Published 2020-11-01